Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials.
Intermittent selective serotonin reuptake inhibitors for premenstrual syndromes: A systematic review and meta-analysis of randomised trials.
复制标题
间歇性选择性5-羟色胺再摄取抑制剂治疗经前综合征：随机试验的系统回顾和荟萃分析。
DOI：
10.1177/02698811221099645
复制
发表时间：
2023-03
影响因子：
4.1
通讯作者：
Taylor, David
中科院分区：
文献类型：
--
作者：
Reilly, Thomas J.;Wallman, Phoebe;Clark, Ivana;Knox, Clare-Louise;Craig, Michael C.;Taylor, David
关键词：
间歇性（黄体期）服用选择性血清素再摄取抑制剂是治疗经前期综合征（如经前期情感障碍）的一种策略。这避免了长期持续用药所带来的抗抑郁药戒断综合征的风险。
比较间歇用药和持续用药的疗效和可接受性。
我们在 Cochrane 对照试验中央注册库、MEDLINE、EMBASE、PsycINFO、PubMed 和 CINAHL 中检索了针对经前期综合征的选择性血清素再摄取抑制剂间歇用药与持续用药的随机试验。我们提取了反应率、辍药率和症状评分的变化。我们使用随机效应荟萃分析来汇集研究层面的数据，并计算二分法数据的几率比例和连续法数据的标准化平均差。偏倚风险采用 Cochrane 偏倚风险工具进行评估。该研究已在 PROSPERO 注册（CRD42020224176）。
共找到 1841 篇参考文献，其中 8 项研究符合分析条件，共有 460 名参与者。所有纳入的研究都提供了应答率，6 项研究提供了辍学率，5 项研究提供了症状评分。在应答率（几率比：1.0，95% 置信区间（CI）：0.23-4.31，I2 = 71%）、辍药率（几率比：1.26，95% 置信区间（CI）：0.39-4.09，I2 = 33%）或症状变化（标准化平均差：0.04，95% 置信区间（CI）：-0.27-0.35，I2 = 39%）方面，间歇用药和持续用药之间没有统计学意义上的差异。所有研究均存在中度或高度偏倚风险。
由于间歇性给药可避免可能出现的戒断症状，因此在此类患者中应更多地考虑间歇性给药。
Intermittent (luteal phase) dosing of selective serotonin reuptake inhibitors is one treatment strategy for premenstrual syndromes such as premenstrual dysphoric disorder. This avoids the risk of the antidepressant withdrawal syndrome associated with long-term continuous dosing. To compare intermittent dosing to continuous dosing in terms of efficacy and acceptability. We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, PsycINFO, PubMed and CINAHL for randomised trials of intermittent compared with continuous dosing of selective serotonin reuptake inhibitors in premenstrual syndromes. We extracted response rates, dropout rates and changes in symptom scores. We used random effects meta-analyses to pool study-level data and calculated odds ratio for dichotomous data and standardised mean difference for continuous data. Risk of bias was assessed using the Cochrane risk-of-bias tool. The study was registered with PROSPERO (CRD42020224176). A total of 1841 references were identified, with eight studies being eligible for analysis, consisting of a total of 460 participants. All included studies provided response rates, six provided dropout rates and five provided symptom scores. There was no statistically significant differences between intermittent and continuous dosing in terms of response rate (odds ratio: 1.0, 95% confidence interval (CI): 0.23–4.31, I2 = 71%), dropout rate (odds ratio 1.26, 95% CI: 0.39–4.09, I2 = 33%) or symptom change (standardised mean difference: 0.04, 95% CI: −0.27 to 0.35, I2 = 39%). All studies had a moderate or high risk of bias. Since intermittent dosing avoids the potential for withdrawal symptoms, it should be considered more commonly in this patient population.
登录
查看更多内容
影响因子：
15.8
作者：
Moher D;Liberati A;Tetzlaff J;Altman DG;PRISMA Group
通讯作者：
PRISMA Group
影响因子：
5
作者：
Hantsoo, Liisa;Epperson, C. Neill
通讯作者：
Epperson, C. Neill
影响因子：
9.8
作者：
Pearlstein, T;Joliat, MJ;Miner, CM
通讯作者：
Miner, CM
DOI：
10.1177/2515245918770963
发表时间：
2018-06-01
影响因子：
13.6
作者：
Lakens, Daniel;Scheel, Anne M.;Isager, Peder M.
通讯作者：
Isager, Peder M.
影响因子：
10.5
作者：
Harmer, Catherine J.;Goodwin, Guy M.;Cowen, Philip J.
通讯作者：
Cowen, Philip J.